Alimentary Pharmacology & Therapeutics

Review article: management of patients with chronic hepatitis C virus infection and `normal' alanine aminotransferase activity
pp. 1133-1149(17)
Authors: ZEUZEM, S.; ALBERTI, A.; ROSENBERG, W.; MARCELLIN, P.; DIAGO, M.; NEGRO, F.; PRATI, D.; PUOTI, C.; ROBERTS, S. K.; SHIFFMAN, M. L.

Review article: alcoholic liver disease - pathophysiological aspects and risk factors
pp. 1151-1161(11)
Authors: GRAMENZI, A.; CAPUTO, F.; BISELLI, M.; KURIA, F.; LOGGI, E.; ANDREONE, P.; BERNARDI, M.

Review article: immune suppression and colorectal cancer
pp. 1163-1177(15)
Authors: EVANS, C.; DALGLEISH, A. G.; KUMAR, D.

Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study
pp. 1179-1186(8)
Authors: YUEN, M.-F.; TAM, S.; FUNG, J.; WONG, D. K.-H.; WONG, B. C.-Y.; LAI, C.-L.

Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic
pp. 1187-1195(9)
Authors: DE VALLE, M. B.; AV KLINTEBERG, V.; ALEM, N.; OLSSON, R.; BJÖRNSSON, E.

Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis
pp. 1197-1205(9)
Authors: MIYAKE, Y.; IWASAKI, Y.; TERADA, R.; OKAMAOTO, R.; IKEDA, H.; MAKINO, Y.; KOBASHI, H.; TAKAGUCHI, K.; SAKAGUCHI, K.; SHIRATORI, Y.

Effects of phlebotomy therapy on cytochrome P450 2e1 activity and oxidative stress markers in dysmetabolic iron overload syndrome: a randomized trial
pp. 1207-1213(7)
Authors: LAINÉ, F.; REYMANN, J. M.; MOREL, F.; LANGOUËT, S.; PERRIN, M.; GUILLYGOMARC'H, A.; BRISSOT, P.; TURMEL, V.; MOUCHEL, C.; PAPE, D.; BELLISSANT, E.; DEUGNIER, Y.

Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease
pp. 1215-1222(8)
Authors: WONG, V. W. S.; HUI, A. Y.; TSANG, S. W. C.; CHAN, J. L. Y.; WONG, G. L. H.; CHAN, A. W. H.; SO, W. Y.; CHENG, A. Y. S.; TONG, P. C. Y.; CHAN, F. K. L.; SUNG, J. J. Y.; CHAN, H. L. Y.

Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C
pp. 1223-1230(8)
Authors: CASTERA, L.; CONSTANT, A.; HENRY, C.; CHAMPBENOIT, P.; BERNARD, P.-H.; DE LEDINGHEN, V.; DEMOTES-MAINARD, J.; COUZIGOU, P.

Survival and dependence on home parenteral nutrition: experience over a 25-year period in a UK referral centre
pp. 1231-1240(10)
Authors: LLOYD, D. A. J.; VEGA, R.; BASSETT, P.; FORBES, A.; GABE, S. M.

A prospective 1-year follow-up study in patients with functional or organic dyspepsia: changes in gastrointestinal symptoms, mental distress and fear of serious illness
pp. 1241-1246(6)
Authors: PAJALA, M.; HEIKKINEN, M.; HINTIKKA, J.

Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding
pp. 1247-1255(9)
Authors: KEYVANI, L.; MURTHY, S.; LEESON, S.; TARGOWNIK, L. E.

Serum bilirubin and risk of colorectal cancer
pp. 1257-1259(3)
Authors: Zucker, S. D.; Benedict, M.; Sherman, K. E.

Serum bilirubin and risk of colorectal cancer: authors' reply
pp. 1259-1261(3)
Authors: Ioannou, G. N.; Liou, I. W.; Weiss, N. S.

CagA status and successful eradication of Helicobacter pylori
pp. 1261-1263(3)
Authors: Treiber, G.; Malfertheiner, P.

CagA status and successful eradication of Helicobacter pylori: authors' reply
pp. 1263-1263(1)
Authors: Matsuo, K.; Suzuki, T.; Tajima, K.

Motor disturbances participate in the pathogenesis of eosinophilic oesophagitis, beyond the fibrous remodelling of the oesophagus
pp. 1264-1267(4)
Author: Lucendo, A. J.

Erratum
pp. 1268-1268(1)

Addendum
pp. 1268-1268(1)